Phase
Condition
Diabetes Mellitus, Type 2
Treatment
MK-1403 + additive coformulation
Placebo + additive coformulation
Clinical Study ID
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Has a confirmed diagnosis of Type 2 diabetes mellitus (T2DM)
Has body mass index (BMI) between 18 and 40 kg/m^2, inclusive
Exclusion
Exclusion Criteria:
Has Type 1 diabetes mellitus or secondary types of diabetes
Has a history of congestive heart failure (New York Heart Association [NYHA] Class 3or 4)
Has history of myocardial infarction, uncontrolled arrhythmias, cardiacrevascularization, angina, unstable peripheral arterial disease and/or stroke
Has history of cancer (malignancy)
Has positive test(s) for hepatitis B surface antigen (HBsAg), hepatitis Cantibodies, or human immunodeficiency virus (HIV)
Has a history of gastrointestinal (GI) disease which might affect food and drugabsorption, or has had gastric bypass or similar surgery
Study Design
Connect with a study center
ProSciento Inc. ( Site 0001)
Chula Vista, California 91911
United StatesActive - Recruiting
Advanced Pharma CR, LLC ( Site 0003)
Miami, Florida 33147
United StatesActive - Recruiting
QPS-MRA, LLC ( Site 0004)
South Miami, Florida 33143
United StatesActive - Recruiting
Advanced Pharma CR, LLC ( Site 0003)
Miami 4164138, Florida 4155751 33147
United StatesActive - Recruiting
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0005)
Springfield, Missouri 65802
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.